9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma

Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 32

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To test the impact of the addition of axitinib to standaard chemotherapy treatment on histology samples,  the side effects of the standard chemotherapy and the additional risks related to axitinib use,  ,

Interventions: axitinib, chemotherapy

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: November 13, 2012

Completion Date: May 6, 2013

Last  Posted Date: February 28, 2017

Location: Antoni van Leeuwenhoekziekenhuis (NKI-AVL), Amsterdam, Noord-Holland, Netherlands

Website Link: https://ClinicalTrials.gov/show/NCT01211275

Was this article helpful?
Dislike 0